ALK and Bradycardia: A meta-analysis suggested that the new generation of ALK inhibitors such as alectinib, brigatinib, or lorlatinib was associated with a similar risk of bradycardia when compared with crizotinib (estimated at around 8%), while the risk was lower during the ceritinib treatment [78].